# NeuroBionics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurobionics

- Industry: Medical Devices & Equipment
- Headquarters: Cambridge, US
- Website: www.neurobionics.io
- Total disclosed funding: $5M
- Latest round: Seed (Jan 16, 2025)
- Investors on record: 3

## About

Established in 2023 and based in Massachusetts, US, NeuroBionics Inc. operates as a neurotechnology company that engages in the development of advanced bioelectronic devices that enhance neuromodulation therapy, utilizing neural interfaces for minimally invasive treatment of neurological disorders. In January 2025, NeuroBionics Inc. raised USD 5 million in seed funding led by investor Dolby Family Ventures, with participation from other investors Future Ventures and GreyMatter. The firm, as of January 2025, is led by its founder and CEO, MJ Antonini.

The company's core product is a multifunctional neural interface that employs hair-thin, flexible bioelectronic fibers capable of sensing and modulating electrical, chemical, and mechanical signals within the body. This device is specifically engineered to facilitate deep brain stimulation (DBS) delivered via an endovascular approach, thereby eliminating the need for invasive open-brain surgery traditional to current DBS technologies. By providing a minimally invasive option, NeuroBionics addresses the unmet needs of patients suffering from neurological disorders, primarily in serving healthcare providers and neuroscience researchers primarily in North America and Europe.

NeuroBionics generates revenue through direct sales of its bioelectronic devices, focusing on partnerships with healthcare institutions and research organizations. The transaction structure revolves around B2B engagements, where hospitals and clinics acquire their flagship products for patient treatment, while researchers utilize their devices for clinical studies.

The company plans to utilize the January 2025 funding to support the development of its clinical device and accelerate its safety and efficacy in pre-clinical studies.

## Funding rounds

- Seed, Jan 16, 2025, $5M — Dolby Family Ventures, Future Ventures, GreyMatter

## Investors

- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Seed
- Future Ventures — Seed
- GreyMatter (https://capitalatlas.ai/funds/greymatter) — Seed